In order to evaluate the efficacy of LEV in pharmacoresistant continous spikes and waves during slow sleep (CSWS) we tested its efficacy and safety in 16 children with CSWS affected by partial epilepsy of different nature (7 symptomatic, 6 cryptogenic, 3 idiopathic) at the dose of 25-50 mg/Kg/die for a period of 2 months to 3 years. Following the good results (disappearance of EEG abnormalities both at wake and during sleep in 4 cases (25%), their reduction to more than 50% in 5 (31.5%)) and the low rate of adverse events (3 drop out cases) the AA stress the possible effectiveness of LEV in children with CSWS.

Efficacy of Levetiracetam in treatment of continous spike wave during sleep (CSWS)

DARRA, Francesca;
2004-01-01

Abstract

In order to evaluate the efficacy of LEV in pharmacoresistant continous spikes and waves during slow sleep (CSWS) we tested its efficacy and safety in 16 children with CSWS affected by partial epilepsy of different nature (7 symptomatic, 6 cryptogenic, 3 idiopathic) at the dose of 25-50 mg/Kg/die for a period of 2 months to 3 years. Following the good results (disappearance of EEG abnormalities both at wake and during sleep in 4 cases (25%), their reduction to more than 50% in 5 (31.5%)) and the low rate of adverse events (3 drop out cases) the AA stress the possible effectiveness of LEV in children with CSWS.
2004
Continuous spike and waves
File in questo prodotto:
File Dimensione Formato  
2004 Boll LICE Darra.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Accesso ristretto
Dimensione 2.56 MB
Formato Adobe PDF
2.56 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/478390
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact